Coeptis Therapeutics Holdings, Inc. WarrantsCOEPW
About: Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
Employees: 7
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 12 [Q4 2024] → 12 (+0) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.44% less ownership
Funds ownership: 2.36% [Q4 2024] → 1.92% (-0.44%) [Q1 2025]
57% less capital invested
Capital invested by funds: $20.4K [Q4 2024] → $8.72K (-$11.6K) [Q1 2025]
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for COEPW.
Financial journalist opinion
We haven’t received any recent news articles for COEPW.